200 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28117205	13	Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L.	Baylor University
10617079	3	Tokaramide A, a new cathepsin B inhibitor from the marine sponge Theonella aff. mirabilis.	The University of Tokyo
27994740	41	Dipeptidyl Nitroalkenes as Potent Reversible Inhibitors of Cysteine Proteases Rhodesain and Cruzain.	Universitat Jaume I
27214508	43	Straightforward synthesis of 2,4,6-trisubstituted 1,3,5-triazine compounds targeting cysteine cathepsins K and S.	Cnrs
27690432	75	Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).	Charles River Discovery Research Services
26985310	8	Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome.	Whitman College
26985300	110	Cathepsin B Inhibitors: Combining Dipeptide Nitriles with an Occluding Loop Recognition Element by Click Chemistry.	University of Bonn
26462052	29	Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.	Baylor University
25865131	40	Synthesis and biological evaluation of open-chain analogs of cyclic peptides as inhibitors of cellular Shp2 activity.	Hebei University of Science & Technology
24913985	73	SAR studies of differently functionalized chalcones based hydrazones and their cyclized derivatives as inhibitors of mammalian cathepsin B and cathepsin H.	Kurukshetra University
25571794	40	Structure-based design and optimization of potent inhibitors of the adenoviral protease.	Novartis Institute For Biomedical Research
25411915	54	8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors.	Array Biopharma
25375026	14	Structures and bioactivities of dihydrochalcones from Metrodorea stipularis.	Universidade Federal De S£O Carlos
25365789	83	The discovery of potent, selective, and reversible inhibitors of the house dust mite peptidase allergen Der p 1: an innovative approach to the treatment of allergic asthma.	Domainex
25313316	20	3-Cyano-3-aza-ß-amino Acid Derivatives as Inhibitors of Human Cysteine Cathepsins.	University of Bonn
24915003	34	Probing of primed and unprimed sites of calpains: Design, synthesis and evaluation of epoxysuccinyl-peptide derivatives as selective inhibitors.	E£Tv£S Lor£Nd University (Elte)
24592859	59	Cathepsin C inhibitors: property optimization and identification of a clinical candidate.	Astrazeneca
24524217	65	Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.	Hokkaido University
24642566	17	Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H.	Kurukshetra University
23252745	86	Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.	University of Ljubljana
24900293	78	Discovery of novel cyanamide-based inhibitors of cathepsin C.	TBA
19616430	120	Design of selective Cathepsin inhibitors.	Astrazeneca
16546382	100	Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.	Celera Genomics
23122525	9	Fluorescent nitrile-based inhibitors of cysteine cathepsins.	University of Bonn
21413808	170	Synopsis of some recent tactical application of bioisosteres in drug design.	Bristol-Myers Squibb Pharmaceutical Research and Development
24900408	4	Nonpeptidic lysosomal modulators derived from z-phe-ala-diazomethylketone for treating protein accumulation diseases.	TBA
22984809	111	Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.	Astrazeneca
22742641	113	(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.	Astrazeneca
22686657	60	Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F.	University of Bonn
22950366	6	Thrombin inhibitors from the freshwater cyanobacterium Anabaena compacta.	Hokkaido University
22858142	121	Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.	Astrazeneca
24900494	72	Synthesis and biochemical evaluation of thiochromanone thiosemicarbazone analogues as inhibitors of cathepsin L.	TBA
22236250	16	Exploring activity cliffs in medicinal chemistry.	Rheinische Friedrich-Wilhelms-Universit£T
21128614	76	Structural optimization of azadipeptide nitriles strongly increases association rates and allows the development of selective cathepsin inhibitors.	University of Bonn
20598553	38	Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors.	Universit£
19709887	25	Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors.	Universit£
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
18995931	16	Natural polyprenylated benzophenones inhibiting cysteine and serine proteases.	Federal University of Alfenas
19419206	77	Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity.	Ewha Womans University
17535802	91	Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.	Merck Research Laboratories
18420405	26	Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB.	University of California
18053726	364	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.	Johnson & Johnson Pharmaceutical Research & Development
18289850	4	Cathepsin B inhibitory activities of phthalates isolated from a marine Pseudomonas strain.	Pukyong National University
18232656	30	Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors.	University of Messina
18226527	80	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.	Merck Frosst Centre For Therapeutic Research
16185867	5	Novel cell-penetrating alpha-keto-amide calpain inhibitors as potential treatment for muscular dystrophy.	Santhera Pharmaceuticals
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
9784105	68	Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption.	Takeda Chemical Industries
9667954	47	D-amino acid containing, high-affinity inhibitors of recombinant human calpain I.	Cephalon
14980679	30	Dipeptidyl aspartyl fluoromethylketones as potent caspase-3 inhibitors: SAR of the P2 amino acid.	Maxim Pharmaceuticals
11055335	27	Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.	Boehringer Ingelheim Pharmaceuticals
	11	Peptidyl aldehyde derivatives as potent and selective inhibitors of cathepsin L	TBA
22019466	13	Design, synthesis and biological evaluation of peptidyl-vinylaminophosphonates as novel cysteine protease inhibitors.	National Chemical Laboratory (Csir-Ncl)
21420760	8	Peptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitors.	University of Messina
21849222	50	Discovery and kinetic evaluation of 6-substituted 4-benzylthio-1,3,5-triazin-2(1H)-ones as inhibitors of cathepsin B.	University of Ljubljana
20823284	9	Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.	Boehringer Ingelheim (Canada)
21227690	68	1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors: separation of desired cellular activity from undesired tissue accumulation through optimization of basic nitrogen pka.	Merck Research Laboratories
21041084	102	Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease.	Merck Research Laboratories
21030256	61	Trifluoromethylphenyl as P2 for ketoamide-based cathepsin S inhibitors.	Merck Research Laboratories
20933415	50	Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L.	Baylor University
20843687	60	Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.	Merck Research Laboratories
20690647	33	Peptidyl alpha-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors.	Georgia Institute of Technology
19841155	29	MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.	Merck Research Laboratories
20692829	21	Allicin and derivates are cysteine protease inhibitors with antiparasitic activity.	University of WüRzburg
20594841	123	2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors.	Merck Research Laboratories
19715342	19	On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.	University of Duisburg-Essen
20153187	32	Dioxo-triazines as a novel series of cathepsin K inhibitors.	Schering-Plough
20149657	53	Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors.	Schering-Plough
19665376	48	Design and synthesis of dipeptidyl nitriles as potent, selective, and reversible inhibitors of cathepsin C.	Merck Frosst Canada
20089402	72	Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors.	Baylor University
19769357	93	Structure-guided development of selective TbcatB inhibitors.	University of California
	10	Nonpeptidic inhibitors of recombinant human calpain I	TBA
	2	Oligopresentation of protease inhibitors with β-cyclodextrin as template	TBA
	22	Inhibition of human erythrocyte calpain I by novel quinolinecarboxamides	TBA
	4	Design of a new selective cysteine protease inactivator and its mechanistic implications	TBA
19296600	14	Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors.	University of Messina
19231183	44	5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.	Astrazeneca
18951789	1	Possible involvement of radical intermediates in the inhibition of cysteine proteases by allenyl esters and amides.	University of Toyama
18789705	6	Peptidyl epoxides extended in the P' direction as cysteine protease inhibitors: effect on affinity and mechanism of inhibition.	Bar-Ilan University
18694642	6	Synthesis and calpain inhibitory activity of peptidomimetic compounds with constrained amino acids at the P2 position.	The University of Tennessee Health Science Center
18571402	24	Effect of novel N-cyano-tetrahydro-pyridazine compounds, a class of cathepsin K inhibitors, on the bone resorptive activity of mature osteoclasts.	Korea Research Institute of Chemical Technology
18313933	18	Substrate optimization for monitoring cathepsin C activity in live cells.	Genomics Institute of The Novartis Research Foundation
17845856	1	Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.	LinköPing University
17656088	15	Identification and characterization of 3-substituted pyrazolyl esters as alternate substrates for cathepsin B: the confounding effects of DTT and cysteine in biological assays.	University of Pennsylvania
17544269	30	Primary amides as selective inhibitors of cathepsin K.	Merck Frosst Centre For Therapeutic Research
17196818	90	Bicyclic carbamates as inhibitors of papain-like cathepsin proteases.	The Genomics Institute of The Novartis Research Foundation
17049233	82	Design of potent inhibitors of human beta-secretase. Part 2.	Pfizer
16913717	42	Synthesis, calpain inhibitory activity, and cytotoxicity of P2-substituted proline and thiaproline peptidyl aldehydes and peptidyl alpha-ketoamides.	The University of Tennessee Health Science Center
16750630	28	Design and synthesis of tetracyclic nonpeptidic biaryl nitrile inhibitors of cathepsin K.	Celera Genomics
16686537	165	Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.	Celera
16647256	16	Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors.	Arpida
16412635	4	A novel series of urea-based peptidomimetic calpain inhibitors.	The University of Tennessee Health Science Center
16302794	53	Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.	Celera Genomics
16290936	69	Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?	Glaxosmithkline
16250645	35	Azepanone-based inhibitors of human cathepsin L.	Glaxosmithkline
16154747	37	Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K.	Merck Frosst Centre For Therapeutic Research
15982880	86	P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.	Glaxosmithkline
15896958	32	Acyclic cyanamide-based inhibitors of cathepsin K.	Glaxosmithkline
15837295	55	A structural screening approach to ketoamide-based inhibitors of cathepsin K.	Glaxosmithkline
15780613	28	Novel and potent cyclic cyanamide-based cathepsin K inhibitors.	Glaxosmithkline
15634028	5	Retro hydrazino-azapeptoids as peptidomimetics of proteasome inhibitors.	Université
15588093	3	A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.	Boehringer Ingelheim (Canada)
15380210	18	Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I).	University of Southern California
15341970	59	P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors.	Eli Lilly
15341947	57	Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.	Glaxosmithkline
15261289	38	Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors.	Merck Frosst Centre For Therapeutic Research
15177446	41	Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitors.	Glaxosmithkline
14684338	44	P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl alpha-ketoamide based HCV protease inhibitors.	Eli Lilly
14684304	41	(4-Piperidinylphenyl)aminoethyl amides as a novel class of non-covalent cathepsin K inhibitors.	Amgen
14592520	41	N-arylaminonitriles as bioavailable peptidomimetic inhibitors of cathepsin B.	Novartis Institute of Biomedical Research
12781193	36	3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P2 elements for selectivity.	Ligand Pharmaceuticals
12773044	18	Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: discovery of potent water-soluble calpain inhibitors with oral bioavailability.	Abbott
12617890	9	Peptidyl aldehyde inhibitors of calpain incorporating P2-proline mimetics.	University of Tennessee Health Science Center
12593666	30	Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor.	Senju Pharmaceutical
12431059	27	Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides.	National Research Council of Canada
12419374	45	6-Acylamino-penam derivatives: synthesis and inhibition of cathepsins B, L, K, and S.	Currently Naeja Pharmaceutical
12419373	18	Design and synthesis of 6-substituted amino-4-oxa-1-azabicyclo[3,2,0]heptan-7-one derivatives as cysteine proteases inhibitors.	Currently Naeja Pharmaceutical
12270191	36	General solid-phase method to prepare novel cyclic ketone inhibitors of the cysteine protease cruzain.	University of California
12270170	42	Novel route to the synthesis of peptides containing 2-amino-1'-hydroxymethyl ketones and their application as cathepsin K inhibitors.	Celera
12213061	23	Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases.	University of Gda£?Sk
11992771	19	Discovery of phenyl alanine derived ketoamides carrying benzoyl residues as novel calpain inhibitors.	Abbott
11806719	61	Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis.	University of California
11741472	45	Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design.	Novartis Pharmaceuticals
32336669	6	Cytotoxicity of 4-substituted quinoline derivatives: Anticancer and antileishmanial potential.	Universidade De Mogi Das Cruzes (Umc)
11356112	175	Potent reversible inhibitors of the protein tyrosine phosphatase CD45.	Astrazeneca Pharmaceuticals
11311061	40	Azepanone-based inhibitors of human and rat cathepsin K.	Glaxosmithkline
11141092	85	Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.	Merck Frosst Centre For Therapeutic Research
11086714	10	Synthesis and calpain inhibitory activity of alpha-ketoamides with 2,3-methanoleucine stereoisomers at the P2 position.	The University of Tennessee Health Science Center
27563406	128	Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.	Roche Pharma Research and Early Development
11012026	18	Synthesis and biological evaluation of novel piperidine carboxamide derived calpain inhibitors.	Knoll
10508448	11	Combinatorial library of serine and cysteine protease inhibitors that interact with both the S and S' binding sites.	Brown University
31145622	91	Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.	National Institute of Biological Sciences (Nibs)
31317731	3	Naturally Occurring Lumazines.	University of Auckland
30773420	16	Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes.	Jilin University
9873610	48	Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.	Boehringer Ingelheim (Canada)
9873596	18	P2-proline-derived inhibitors of calpain I.	Cephalon
9871780	85	Inhibition of human cytomegalovirus protease N(o) with monocyclic beta-lactams.	Boehringer Ingelheim (Canada)
32227886	6	Use of Non-Natural Amino Acids for the Design and Synthesis of a Selective, Cell-Permeable MALT1 Activity-Based Probe.	Ku Leuven
9871680	5	Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.	Proscript
32125159	60	Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity.	Texas A&M University
31158752	6	Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor.	University of Nebraska Medical Center
9733481	31	Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.	Smithkline Beecham Pharmaceuticals
30473362	15	Cathepsin B: Active site mapping with peptidic substrates and inhibitors.	University of Bonn
9406601	109	Peptidomimetic inhibitors of the human cytomegalovirus protease.	Boehringer Ingelheim
31361135	17	Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity?	University of S£O Paulo
30455147	7	Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments.	University of Houston
8831774	261	Novel peptidyl alpha-keto amide inhibitors of calpains and other cysteine proteases.	Georgia Institute of Technology
26522952	44	Development of a potent and selective cell penetrant Legumain inhibitor.	Queen'S University Belfast
24364476	9	The marine cyanobacterial metabolite gallinamide A is a potent and selective inhibitor of human cathepsin L.	University of California
23623677	2	Development of cell-active non-peptidyl inhibitors of cysteine cathepsins.	The City University of New York
23608763	38	Chalcones, inhibitors for topoisomerase I and cathepsin B and L, as potential anti-cancer agents.	Cha University
23562595	98	Identification of new peptide amides as selective cathepsin L inhibitors: the first step towards selective irreversible inhibitors?	National Institute of Biology
23540644	59	Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks.	Baylor University
7650671	15	Vinyl sulfones as mechanism-based cysteine protease inhibitors.	Khepri Pharmaceuticals
12662104	1	Two new carbazole alkaloids from Murraya koenigii.	Chinese Academy of Sciences
30029081	31	New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8.	Johannes Gutenberg-Universit£T Mainz
30049585	73	Selective inhibition of human cathepsin S by 2,4,6-trisubstituted 1,3,5-triazine analogs.	Universit£
30037754	64	Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates.	Universitat Jaume I
29615344	101	Peptidomimetic nitrile inhibitors of malarial protease falcipain-2 with high selectivity against human cathepsins.	Irbm Science Park
29503024	138	Cathepsin B inhibitors: Further exploration of the nitroxoline core.	University of Ljubljana
29590750	58	Repurposing a Library of Human Cathepsin L Ligands: Identification of Macrocyclic Lactams as Potent Rhodesain and Trypanosoma brucei Inhibitors.	Eth Zurich
28759231	46	Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides.	Abbvie Deutschland
28122457	12	Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets.	Taipei Medical University
21635213	8	In vitro effects of some anabolic compounds on erythrocyte carbonic anhydrase I and II.	Balikesir University
	16	Design, synthesis and evaluation of trisubstituted thiazoles targeting plasmodium falciparum cysteine proteases	University, Mississippi
15608078	35	Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.	Abbott Laboratories
11805207	8	Preclinical pharmacology of fiduxosin, a novel alpha(1)-adrenoceptor antagonist with uroselective properties.	Abbott Laboratories
10455251	10	RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist.	Roche Bioscience